The Journal of Urology
Volume 180, Issue 4 , Pages 1219-1222 , October 2008

It's Time to Abandon an Upper Limit of Normal for Prostate Specific Antigen: Assessing the Risk of Prostate Cancer

  • Ian M. Thompson

      Affiliations

    • University of Texas Health Science Center at San Antonio, San Antonio, Texas
    • Financial interest and/or other relationship with Mission Pharmacal, Johnson & Johnson and AstraZeneca.
    • ,
  • Donna P. Ankerst

      Affiliations

    • University of Texas Health Science Center at San Antonio, San Antonio, Texas
    • ,
  • Ruth Etzioni

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Thomas Wang

      Affiliations

    • Massachusetts General Hospital, Boston, Massachusetts

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by Public Health Service Grant UO1-CA86402, Early Detection Research Network, National Cancer Institute, National Institutes of Health and San Antonio Cancer Institute P30 CA 54174.

PII: S0022-5347(08)01907-1

doi: 10.1016/j.juro.2008.07.089

The Journal of Urology
Volume 180, Issue 4 , Pages 1219-1222 , October 2008

Article Tools

* Image Usage & Resolution